KR20200103018A - Gpcr 헤테로머 억제제 및 이의 용도 - Google Patents
Gpcr 헤테로머 억제제 및 이의 용도 Download PDFInfo
- Publication number
- KR20200103018A KR20200103018A KR1020207019080A KR20207019080A KR20200103018A KR 20200103018 A KR20200103018 A KR 20200103018A KR 1020207019080 A KR1020207019080 A KR 1020207019080A KR 20207019080 A KR20207019080 A KR 20207019080A KR 20200103018 A KR20200103018 A KR 20200103018A
- Authority
- KR
- South Korea
- Prior art keywords
- cxcr4
- gpcrx
- inhibitor
- treatment
- inhibition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G01N33/57484—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020267002674A KR20260035212A (ko) | 2017-12-19 | 2018-12-18 | Gpcr 헤테로머 억제제들 및 이의 용도 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607876P | 2017-12-19 | 2017-12-19 | |
| US62/607,876 | 2017-12-19 | ||
| US201862679598P | 2018-06-01 | 2018-06-01 | |
| US62/679,598 | 2018-06-01 | ||
| US201862732946P | 2018-09-18 | 2018-09-18 | |
| US62/732,946 | 2018-09-18 | ||
| PCT/KR2018/016166 WO2019124951A1 (en) | 2017-12-19 | 2018-12-18 | Gpcr heteromer inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267002674A Division KR20260035212A (ko) | 2017-12-19 | 2018-12-18 | Gpcr 헤테로머 억제제들 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200103018A true KR20200103018A (ko) | 2020-09-01 |
Family
ID=66813757
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207019080A Ceased KR20200103018A (ko) | 2017-12-19 | 2018-12-18 | Gpcr 헤테로머 억제제 및 이의 용도 |
| KR1020267002674A Pending KR20260035212A (ko) | 2017-12-19 | 2018-12-18 | Gpcr 헤테로머 억제제들 및 이의 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267002674A Pending KR20260035212A (ko) | 2017-12-19 | 2018-12-18 | Gpcr 헤테로머 억제제들 및 이의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10709763B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3900712A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7517986B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20200103018A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111741752A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018388302B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020012075A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3086337A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI818938B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019124951A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200103018A (ko) | 2017-12-19 | 2020-09-01 | 주식회사 지피씨알 | Gpcr 헤테로머 억제제 및 이의 용도 |
| JP7849948B2 (ja) | 2018-03-05 | 2026-04-22 | テオン セラピューティクス,インク. | アデノシン受容体アンタゴニストおよびその使用 |
| KR20220078526A (ko) * | 2019-03-06 | 2022-06-10 | 인메드 파마슈티컬스 인코포레이티드 | 이종 시스템에서 테르페노이드 또는 칸나비노이드의 생합성을 위한 조성물 및 방법 |
| KR20210156849A (ko) * | 2019-05-17 | 2021-12-27 | 주식회사 지피씨알 | Gpcr 헤테로머 저해제들 및 이의 용도 |
| KR102268983B1 (ko) * | 2019-09-11 | 2021-06-24 | 경북대학교 산학협력단 | 엔도테린 수용체 억제제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도 |
| CN110755431B (zh) * | 2019-11-08 | 2023-02-28 | 暨南大学 | 地氯雷他定在制备抗肝癌药物中的应用 |
| JPWO2022025168A1 (cg-RX-API-DMAC7.html) * | 2020-07-30 | 2022-02-03 | ||
| EP4196611A1 (en) | 2020-08-15 | 2023-06-21 | Regeneron Pharmaceuticals, Inc. | Treatment of obesity in subjects having variant nucleic acid molecules encoding calcitonin receptor (calcr) |
| CN112807425A (zh) * | 2021-01-14 | 2021-05-18 | 南方医科大学深圳医院 | 一种tTIM融合蛋白疫苗、制备方法及应用 |
| EP4306655A4 (en) * | 2021-08-04 | 2024-08-21 | Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd | PRIMER-PROBE SET, KIT AND DETECTION METHOD FOR DETECTING HUMAN HISTAMINE RECEPTOR HRH1 mRNA |
| CN114574580B (zh) * | 2022-02-14 | 2022-11-29 | 山东大学 | 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用 |
| WO2023211779A1 (en) * | 2022-04-25 | 2023-11-02 | Kallyope, Inc. | Treatment of headache disorders with nk3 modulators |
| AU2023285050A1 (en) * | 2022-06-10 | 2025-01-23 | Gpcr Therapeutics, Inc. | Gpcr inhibitors and uses thereof |
| CN114891742B (zh) * | 2022-06-23 | 2024-06-04 | 杭州中赢生物医疗科技有限公司 | 一种强杀伤性nk细胞的培养基及体外扩增方法 |
| CN116298305B (zh) * | 2023-01-03 | 2024-05-28 | 郑州大学 | 一种抗nt5c1a自身抗体检测方法及体外诊断试剂盒 |
| KR20260011143A (ko) | 2023-04-18 | 2026-01-22 | 칼리오페, 인크. | Nk3 조정제 및 이의 용도 |
| AU2024334309A1 (en) * | 2023-08-30 | 2026-03-05 | Josephine Cardarelli | Gpcr inhibitors and uses thereof |
| CN119345201B (zh) * | 2024-12-25 | 2025-03-18 | 中国人民解放军总医院第三医学中心 | 治疗tfe3基因重排性肾细胞癌的药物或药物组合物及用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998000538A2 (en) | 1996-07-01 | 1998-01-08 | Biosignal Inc. | Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization |
| AU3249997A (en) | 1996-07-01 | 1998-01-21 | Biosignal Inc. | Method of assaying compounds which affect the activity of g protein-coupled receptors based on measurement of receptor oligomerization |
| US6855807B1 (en) | 1999-06-16 | 2005-02-15 | New York University | Heterodimeric opioid G-protein coupled receptors |
| US20010053848A1 (en) | 2000-03-10 | 2001-12-20 | Patel Yogesh C. | Hetero-oligomeric G protein-coupled receptors as novel drug targets |
| CN102302493B (zh) * | 2001-07-31 | 2015-08-12 | 健赞股份有限公司 | 活化祖细胞/干细胞的方法 |
| EP1625159B1 (en) | 2003-05-20 | 2011-03-02 | The University Court Of The University Of Glasgow | Materials and methods relating to g-protein coupled receptor oligomers |
| WO2005103721A1 (en) * | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4) |
| CA2640087A1 (en) * | 2006-01-25 | 2007-08-02 | Mount Sinai School Of Medicine | Methods and compositions for modulating the mobilization of stem cells |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| US9212226B2 (en) * | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| WO2010002468A1 (en) | 2008-07-01 | 2010-01-07 | The Trustees Of Columbia University In The City Of New York | A functional complementation assay for defined gpcr oligomers |
| FR2949156B1 (fr) | 2009-08-13 | 2016-04-15 | Cis-Bio Int | Methode de determination de la liaison d'un compose donne a un recepteur membranaire |
| WO2011091435A2 (en) | 2010-01-25 | 2011-07-28 | Mount Sinai School Of Medicine | Methods of treating liver disease |
| JP2011168567A (ja) * | 2010-02-22 | 2011-09-01 | Kyoto Univ | 再発癌の予防または治療用医薬 |
| KR101029972B1 (ko) | 2010-06-18 | 2011-04-20 | 서울대학교산학협력단 | 바이러스 벡터를 이용하여 단백질의 상호작용을 측정하는 방법 |
| WO2012047339A2 (en) * | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| US9267934B2 (en) * | 2010-10-26 | 2016-02-23 | University Of South Alabama | Methods and compositions for ameliorating pancreatic cancer |
| MX371455B (es) * | 2013-08-02 | 2020-01-28 | Pfizer | Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco. |
| EP3030322A2 (en) * | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| CN103536594A (zh) * | 2013-10-21 | 2014-01-29 | 江苏亚虹医药科技有限公司 | G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途 |
| WO2015095973A1 (en) | 2013-12-23 | 2015-07-02 | Université de Montréal | Systems and methods for the monitoring of protein complex formation in cells |
| DK3242685T3 (da) * | 2015-01-09 | 2022-07-25 | Adalta Ltd | Cxcr4-bindende molekyler |
| WO2017020128A1 (en) * | 2015-08-03 | 2017-02-09 | Université de Montréal | Markers for acute myeloid leukemias with core binding factor rearrangements and other genetic subtypes and uses thereof |
| KR20200103018A (ko) | 2017-12-19 | 2020-09-01 | 주식회사 지피씨알 | Gpcr 헤테로머 억제제 및 이의 용도 |
-
2018
- 2018-12-18 KR KR1020207019080A patent/KR20200103018A/ko not_active Ceased
- 2018-12-18 KR KR1020267002674A patent/KR20260035212A/ko active Pending
- 2018-12-18 CA CA3086337A patent/CA3086337A1/en active Pending
- 2018-12-18 JP JP2020535043A patent/JP7517986B2/ja active Active
- 2018-12-18 WO PCT/KR2018/016166 patent/WO2019124951A1/en not_active Ceased
- 2018-12-18 BR BR112020012075-8A patent/BR112020012075A2/pt active Search and Examination
- 2018-12-18 EP EP21174644.1A patent/EP3900712A1/en active Pending
- 2018-12-18 CN CN201880089801.6A patent/CN111741752A/zh active Pending
- 2018-12-18 AU AU2018388302A patent/AU2018388302B2/en active Active
- 2018-12-18 TW TW107145764A patent/TWI818938B/zh active
- 2018-12-18 US US16/224,450 patent/US10709763B2/en active Active
- 2018-12-18 EP EP18892135.7A patent/EP3727371A4/en active Pending
-
2020
- 2020-05-27 US US16/885,196 patent/US11857600B2/en active Active
-
2021
- 2021-04-16 US US17/233,359 patent/US20210268069A1/en not_active Abandoned
-
2024
- 2024-05-01 JP JP2024074184A patent/JP7818648B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018388302A1 (en) | 2020-07-02 |
| JP7517986B2 (ja) | 2024-07-17 |
| US10709763B2 (en) | 2020-07-14 |
| CA3086337A1 (en) | 2019-06-27 |
| CN111741752A (zh) | 2020-10-02 |
| EP3727371A4 (en) | 2021-10-27 |
| JP2021507925A (ja) | 2021-02-25 |
| TW202017598A (zh) | 2020-05-16 |
| BR112020012075A2 (pt) | 2020-12-01 |
| AU2018388302B2 (en) | 2024-10-31 |
| TWI818938B (zh) | 2023-10-21 |
| WO2019124951A9 (en) | 2019-11-07 |
| US20210268069A1 (en) | 2021-09-02 |
| EP3727371A1 (en) | 2020-10-28 |
| KR20260035212A (ko) | 2026-03-12 |
| US20200360478A1 (en) | 2020-11-19 |
| WO2019124951A1 (en) | 2019-06-27 |
| JP2024109616A (ja) | 2024-08-14 |
| EP3900712A1 (en) | 2021-10-27 |
| JP7818648B2 (ja) | 2026-02-20 |
| US11857600B2 (en) | 2024-01-02 |
| US20190183976A1 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11857600B2 (en) | GPCR heteromer inhibitors and uses thereof | |
| Alampour‐Rajabi et al. | MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP‐70 signaling, and lymphocyte chemotaxis | |
| US20220098594A1 (en) | Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence | |
| CN107427574B (zh) | Cxcr4结合分子 | |
| JP2018513384A (ja) | Ror1−ror2結合のモジュレーター | |
| CN107056930A (zh) | 编码突变的人notch受体的多核苷酸 | |
| AU2020278977B2 (en) | GPCR heteromer inhibitors and uses thereof | |
| US7892767B2 (en) | Phosphospecific chemokine receptor antibodies | |
| TWI359271B (en) | Pharmaceutical composition for insulin resistance | |
| JP7621972B2 (ja) | 新規な選択的ackr3調節性物質及びその使用 | |
| HK40062725A (en) | Gpcr heteromer inhibitors and uses thereof | |
| US20160067314A1 (en) | Compositions and methods for inhibiting chemoresistance in cancer and improving response to therapy | |
| JP4188720B2 (ja) | 新規スクリーニング方法 | |
| Wang et al. | G Protein‐Coupled Receptors and Their Mutations in Cancer–A Focus on Adenosine Receptors | |
| HK40066087A (en) | Cxcr4 binding molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| D13-X000 | Search requested |
St.27 status event code: A-1-2-D10-D13-srh-X000 |
|
| D14-X000 | Search report completed |
St.27 status event code: A-1-2-D10-D14-srh-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| B17 | Application discontinued following pre-grant review |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PX0601 | Decision of rejection after re-examination |
St.27 status event code: N-2-6-B10-B17-rex-PX0601 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |